Features

As we near the fourth quarter of 2022, what have been the key mergers and acquisitions thus far in the CDMO/CMO sector and what new CDMOs/CMOs have entered the market? DCAT Value Chain Insights takes a look.

How is current market volatility, led by inflationary pressures, supply-chain disruptions, and geopolitical uncertainty, impacting sourcing and supply decisions? A look at what is on the industry’s radar.

The European Commission proposed this week an emergency intervention in Europe’s energy markets to address recent dramatic price rises as the EU faces the effects of a severe mismatch between energy demand and supply. What is in the proposal?

What are the key issues and trends in play for the rest of 2022? From energy supply to inflationary pressures to new bio/pharmaceutical products launches, DCAT Value Chain Insights takes an inside look of what may be next.  

Led by increased product development of biologics, including new modalities, biomanufacturing continues to be an active area of investment by CDMOs/CMOs. A roundup of the latest expansions.

In May (May 2022), the FDA issued draft guidance to spell out the types of drugs that are vulnerable to shortages and should be subject to risk-management plan reporting. What does the industry think?

A measure of innovation in the bio/pharma industry is to look at “first-in-class” new drug approvals, referring to drugs with new mechanisms of actions than existing therapies. A look at key trends, the companies, and products for first-in-class drugs.

Novartis’ decision to spin out Sandoz, its generics and biosimilars business, into a separate, stand-alone company is the latest move in the highly cost-competitive generics market. What was behind Novartis’ decision, and how does it fit with other recent deals?

How have the bio/pharmaceutical majors performed thus far in 2022? Which companies and products are on the upside, and which companies and products are not meeting expectations? An analysis of first-half 2022 results and key pipeline progress of the top companies.

The industry is moving to meet a deadline of November 27, 2023, for implementing interoperability requirements under the Drug Supply Chain Security Act, which outlines the steps to build an electronic, interoperable system to identify and trace Rx drugs through the supply chain.